Our Pricing

Understanding Wegovy Dose Escalation and Effectiveness

Published on: June 03, 2026

Many patients ask at what dose does wegovy start working for meaningful weight loss. While Wegovy begins influencing appetite regulation from the initial 0.25mg dose, clinical trials demonstrate that noticeable weight reduction typically becomes evident as patients progress to 0.5mg and beyond during the carefully structured dose escalation schedule [1]. At Cured Pharmacy, our UK-registered prescribers guide you through each stage of treatment, with Wegovy available from £79.00 following your free online consultation.

How Wegovy Works From the First Dose

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural hormone your body produces after eating [1]. From the very first 0.25mg injection, semaglutide begins binding to GLP-1 receptors in your brain, pancreas, and digestive system, triggering a cascade of metabolic changes that support weight loss.

The initial dose starts working immediately at a physiological level—slowing gastric emptying, reducing appetite signals, and improving insulin sensitivity [2]. However, the 0.25mg starting dose is intentionally low to allow your body to adapt to the medication and minimise gastrointestinal side effects like nausea and vomiting, which are most common during the first few weeks of treatment.

Most patients report feeling less hungry and experiencing earlier satiety within the first two weeks, even at 0.25mg [1]. This is the medication working as intended, though significant weight loss typically requires progression to higher therapeutic doses.

The Wegovy Dose Escalation Schedule Explained

Wegovy follows a structured monthly dose escalation protocol designed to optimise both effectiveness and tolerability [3]. You begin with 0.25mg once weekly for four weeks, then increase to 0.5mg for another four weeks. The schedule continues with monthly increases to 1mg, 1.7mg, and finally the maintenance dose of 2.4mg.

This gradual escalation is not arbitrary—clinical trials established that stepping up doses monthly significantly reduces the incidence of treatment-discontinuing side effects whilst allowing therapeutic blood levels to build progressively [3]. Each dose level serves a specific purpose: the lower doses prime your system, whilst the higher doses deliver the full weight loss potential demonstrated in clinical trials.

When Does Wegovy Start Working for Weight Loss?

Clinical data from the STEP trials shows that patients typically begin experiencing measurable weight loss during the 0.5mg and 1mg phases [1][2]. In STEP 1, participants lost an average of 5.9% of their body weight by week 20, when most were on 1mg or 1.7mg doses. By week 68, when patients had been on the 2.4mg maintenance dose for several months, average weight loss reached 14.9% [1].

Individual responses vary considerably. Some patients notice significant appetite reduction and early weight loss at 0.5mg, whilst others require the full 2.4mg maintenance dose to achieve optimal results. Your UK prescriber will monitor your progress and may adjust the escalation timeline based on your tolerance and response.

Clinical Evidence: Wegovy Effectiveness Across Doses

The landmark STEP 1 trial enrolled 1,961 adults with obesity or overweight with at least one weight-related condition [1]. Participants receiving Wegovy 2.4mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. Importantly, 86.4% of Wegovy participants achieved at least 5% weight loss, and 69.1% achieved at least 10% weight loss [1].

Dose-response analysis from the STEP programme demonstrates a clear relationship between semaglutide dose and weight loss magnitude [2]. Whilst lower doses produce meaningful results, the 2.4mg maintenance dose consistently delivers superior outcomes across diverse patient populations, including those with type 2 diabetes, cardiovascular disease, and varying baseline BMI levels.

It is worth noting that Wegovy's effects are sustained only with continued use. In STEP 4, participants who discontinued Wegovy after 20 weeks regained two-thirds of their lost weight over the following 48 weeks, whilst those who continued treatment maintained their weight loss and lost additional weight [4].

What to Expect at Each Dose Level

At 0.25mg and 0.5mg, expect appetite suppression and possible mild nausea as your body adapts. Weight loss during these initial eight weeks is typically modest—averaging 2-4% of body weight. At 1mg and 1.7mg, most patients experience more pronounced appetite reduction and accelerated weight loss, averaging 8-12% by month five. The 2.4mg maintenance dose, reached after 16-20 weeks, is where maximum therapeutic effect occurs, with continued weight loss for up to 68 weeks in clinical trials [1][3].

Factors That Influence When Wegovy Starts Working

Your individual response to Wegovy depends on multiple factors beyond dose alone. Baseline metabolic rate, insulin sensitivity, genetic variations in GLP-1 receptor expression, and concurrent medications can all influence how quickly you notice results [2]. Patients with higher baseline BMI often experience more rapid initial weight loss in absolute terms, though percentage reductions may be similar across BMI categories.

Lifestyle factors significantly impact Wegovy's effectiveness at every dose level. Clinical trials required participants to follow a reduced-calorie diet and increase physical activity, and these interventions work synergistically with semaglutide [1]. Patients who maintain consistent dietary changes and regular exercise typically achieve results at lower doses compared to those relying on medication alone.

Adherence to the dosing schedule is critical. Missing doses or delaying escalation can diminish effectiveness and prolong the time to therapeutic benefit. If you miss a dose and it has been less than five days, take it as soon as you remember. If more than five days have passed, skip that dose and resume your regular schedule [3].

Managing Side Effects During Dose Escalation

Gastrointestinal side effects—particularly nausea, vomiting, diarrhoea, and constipation—are most common during the first few weeks of treatment and when increasing doses [3]. In STEP 1, 44.2% of participants reported nausea, though most cases were mild to moderate and resolved within several weeks. Only 4.5% discontinued Wegovy due to gastrointestinal adverse events [1].

To minimise side effects whilst allowing Wegovy to work effectively, eat smaller, more frequent meals rather than large portions. Avoid high-fat and heavily processed foods, which can exacerbate nausea. Stay well-hydrated, particularly if experiencing vomiting or diarrhoea. If side effects are severe or persistent, contact your prescriber—they may recommend staying at your current dose for an additional month before escalating.

Rare but serious side effects include pancreatitis, gallbladder disease, and hypoglycaemia in patients taking other glucose-lowering medications [3]. Seek immediate medical attention if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction. Your Cured Pharmacy prescriber will review your complete medical history to identify any contraindications before prescribing Wegovy.

When to Contact Your Prescriber

Contact your UK prescriber if you experience severe or worsening side effects, have concerns about your dose escalation schedule, or are not experiencing expected weight loss after reaching the 1.7mg or 2.4mg dose. Your prescriber may recommend additional investigations, adjust your treatment plan, or consider alternative weight management options based on your individual response and tolerability.

Getting Started With Wegovy at Cured Pharmacy

At Cured Pharmacy, Wegovy is available from £79.00 following a free online consultation with our UK-registered prescribers. Our clinical team, led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), assesses your medical history, current medications, and weight loss goals to determine whether Wegovy is appropriate for you.

The consultation takes under three minutes to complete and covers essential safety questions about your cardiovascular health, history of pancreatitis or thyroid conditions, and current medications. If approved, your prescription is issued by a UK prescriber and dispensed by our GPhC-registered pharmacy (9012511). We supply only genuine UK-licensed Wegovy pens, delivered discreetly to your door with next-day options available.

We provide transparent upfront pricing—you will see the exact cost before completing your consultation, with no hidden fees or subscription charges. Our clinical team remains available throughout your treatment journey to answer questions about dose escalation, side effect management, and optimising your results. All prescription medications require clinical assessment, and Wegovy is only prescribed to patients who meet MHRA-approved criteria for weight management.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). Retrieved from https://www.medicines.org.uk/emc/product/13799/smpc [accessed 13 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medication licensed by the MHRA for weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity. Individual results may vary. Side effects can occur—read the patient information leaflet carefully and report any concerns to your prescriber.